Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis

AS. Ramalho, E. Fürstová, AM. Vonk, M. Ferrante, C. Verfaillie, L. Dupont, M. Boon, M. Proesmans, JM. Beekman, I. Sarouk, C. Vazquez Cordero, F. Vermeulen, K. De Boeck, Belgian Organoid Project

. 2021 ; 57 (1) : . [pub] 20210105

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026220

RATIONALE: Given the vast number of cystic fibrosis transmembrane conductance regulator (CFTR) mutations, biomarkers predicting benefit from CFTR modulator therapies are needed for subjects with cystic fibrosis (CF). OBJECTIVES: To study CFTR function in organoids of subjects with common and rare CFTR mutations and evaluate correlations between CFTR function and clinical data. METHODS: Intestinal organoids were grown from rectal biopsies in a cohort of 97 subjects with CF. Residual CFTR function was measured by quantifying organoid swelling induced by forskolin and response to modulators by quantifying organoid swelling induced by CFTR correctors, potentiator and their combination. Organoid data were correlated with clinical data from the literature. RESULTS: Across 28 genotypes, residual CFTR function correlated (r2=0.87) with sweat chloride values. When studying the same genotypes, CFTR function rescue by CFTR modulators in organoids correlated tightly with mean improvement in lung function (r2=0.90) and sweat chloride (r2=0.95) reported in clinical trials. We identified candidate genotypes for modulator therapy, such as E92K, Q237E, R334W and L159S. Based on organoid results, two subjects started modulator treatment: one homozygous for complex allele Q359K_T360K, and the second with mutation E60K. Both subjects had major clinical benefit. CONCLUSIONS: Measurements of residual CFTR function and rescue of function by CFTR modulators in intestinal organoids correlate closely with clinical data. Our results for reference genotypes concur with previous results. CFTR function measured in organoids can be used to guide precision medicine in patients with CF, positioning organoids as a potential in vitro model to bring treatment to patients carrying rare CFTR mutations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026220
003      
CZ-PrNML
005      
20211026133113.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1183/13993003.02426-2019 $2 doi
035    __
$a (PubMed)32747394
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ramalho, Anabela S $u Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium
245    10
$a Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis / $c AS. Ramalho, E. Fürstová, AM. Vonk, M. Ferrante, C. Verfaillie, L. Dupont, M. Boon, M. Proesmans, JM. Beekman, I. Sarouk, C. Vazquez Cordero, F. Vermeulen, K. De Boeck, Belgian Organoid Project
520    9_
$a RATIONALE: Given the vast number of cystic fibrosis transmembrane conductance regulator (CFTR) mutations, biomarkers predicting benefit from CFTR modulator therapies are needed for subjects with cystic fibrosis (CF). OBJECTIVES: To study CFTR function in organoids of subjects with common and rare CFTR mutations and evaluate correlations between CFTR function and clinical data. METHODS: Intestinal organoids were grown from rectal biopsies in a cohort of 97 subjects with CF. Residual CFTR function was measured by quantifying organoid swelling induced by forskolin and response to modulators by quantifying organoid swelling induced by CFTR correctors, potentiator and their combination. Organoid data were correlated with clinical data from the literature. RESULTS: Across 28 genotypes, residual CFTR function correlated (r2=0.87) with sweat chloride values. When studying the same genotypes, CFTR function rescue by CFTR modulators in organoids correlated tightly with mean improvement in lung function (r2=0.90) and sweat chloride (r2=0.95) reported in clinical trials. We identified candidate genotypes for modulator therapy, such as E92K, Q237E, R334W and L159S. Based on organoid results, two subjects started modulator treatment: one homozygous for complex allele Q359K_T360K, and the second with mutation E60K. Both subjects had major clinical benefit. CONCLUSIONS: Measurements of residual CFTR function and rescue of function by CFTR modulators in intestinal organoids correlate closely with clinical data. Our results for reference genotypes concur with previous results. CFTR function measured in organoids can be used to guide precision medicine in patients with CF, positioning organoids as a potential in vitro model to bring treatment to patients carrying rare CFTR mutations.
650    12
$a cystická fibróza $x farmakoterapie $x genetika $x metabolismus $7 D003550
650    _2
$a protein CFTR $x genetika $x metabolismus $7 D019005
650    _2
$a homozygot $7 D006720
650    _2
$a lidé $7 D006801
650    _2
$a iontový transport $7 D017136
650    _2
$a mutace $7 D009154
650    _2
$a organoidy $x metabolismus $7 D009940
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fürstová, Eva $u Dept of Pediatrics, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Vonk, Annelotte M $u Dept of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, The Netherlands $u Regenerative Medicine Center, University Medical Centre, Utrecht, The Netherlands
700    1_
$a Ferrante, Marc $u Dept of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven, Leuven, Belgium $u Dept of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
700    1_
$a Verfaillie, Catherine $u Dept of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven, Leuven, Belgium
700    1_
$a Dupont, Lieven $u Dept of Chronic Diseases, Metabolism and Ageing; Pneumology, KU Leuven, Leuven, Belgium $u Dept of Respiratory Diseases, University Hospital of Leuven, Leuven, Belgium
700    1_
$a Boon, Mieke $u Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium $u Dept of Pediatrics, Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium
700    1_
$a Proesmans, Marijke $u Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium $u Dept of Pediatrics, Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium
700    1_
$a Beekman, Jeffrey M $u Dept of Pediatric Pulmonology, Wilhelmina Children's Hospital, University Medical Centre, Utrecht, The Netherlands $u Regenerative Medicine Center, University Medical Centre, Utrecht, The Netherlands
700    1_
$a Sarouk, Ifat $u Pulmonology Pediatrics and National CF Center Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel
700    1_
$a Vazquez Cordero, Carlos $u Pulmonology and Cystic Fibrosis Unit, Cruces University Hospital, Barakaldo, Spain
700    1_
$a Vermeulen, Francois $u Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium $u Dept of Pediatrics, Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium
700    1_
$a De Boeck, Kris $u Dept of Development and Regeneration, Woman and Child Unit, CF Research Lab, KU Leuven, Leuven, Belgium $u Dept of Pediatrics, Pediatric Pulmonology, University Hospital of Leuven, Leuven, Belgium
710    2_
$a Belgian Organoid Project
773    0_
$w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 57, č. 1 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32747394 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133119 $b ABA008
999    __
$a ok $b bmc $g 1715047 $s 1146727
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 57 $c 1 $e 20210105 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace